The trial involved adults and adolescents aged 12 years and above with MOGAD, offering an open-label extension.

The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 ...

Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.

Treatment with satralizumab reduced the risk of new MOGAD relapse by 68% vs placebo. Positive results were announced from a phase 3 trial evaluating satralizumab for the treatment of myelin ...

Add Yahoo as a preferred source to see more of our stories on Google. Have you ever looked up at a “shooting star” and wondered what you’re actually seeing? The terms meteor, meteorite, and meteoroid ...

Meteoroid impacts represent one of the most dynamic interactions between extraterrestrial bodies and the Earth’s atmosphere. When meteoroids enter the atmosphere, they experience rapid deceleration ...